Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Moderna, Inc. (MRNA)

186.84   -7.34 (-3.78%) 08-08 00:41
Open: 189.271 Pre. Close: 194.18
High: 192.39 Low: 182.26
Volume: 5,426,044 Market Cap: 73,092(M)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 192.6 - 193.7 193.7 - 194.7
Low: 179.8 - 180.97 180.97 - 182.02
Close: 185.13 - 187.04 187.04 - 188.75

Technical analysis

as of: 2022-08-05 4:23:53 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 230.59     One year: 269.32
Support: Support1: 166.16    Support2: 146.83
Resistance: Resistance1: 197.42    Resistance2: 230.59
Pivot: 168.42
Moving Average: MA(5): 177.96     MA(20): 168.65
MA(100): 152.66     MA(250): 225.81
MACD: MACD(12,26): 7.2     Signal(9): 5.3
Stochastic oscillator: %K(14,3): 87.4     %D(3): 72.4
RSI: RSI(14): 65.1
52-week: High: 464.85  Low: 115.61
Average Vol(K): 3-Month: 5,434 (K)  10-Days: 4,992 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MRNA ] has closed below upper band by 7.8%. Bollinger Bands are 18.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 03 Aug 2022
Moderna considering creating an mRNA monkeypox vaccine amid growing demand for shots - ABC News

Wed, 03 Aug 2022
Moderna's 2Q earnings beat expectations, but it writes off $500 million in expiring Covid shots - CNBC

Tue, 02 Aug 2022
mRNA vaccines induce faster antibody response against infectious diseases - News-Medical.Net

Tue, 26 Jul 2022
SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children - Science

Tue, 19 Jul 2022
Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination - Science

Tue, 19 Jul 2022
Novavax non-mRNA COVID vaccine gets CDC approval - NPR

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 405 (M)
% Held by Insiders 3.653e+008 (%)
% Held by Institutions 9.4 (%)
Shares Short 16,210 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 1.353e+010
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 66
Operating Margin (%) 71.9
Return on Assets (ttm) 51.9
Return on Equity (ttm) 146
Qtrly Rev. Growth 1
Gross Profit (p.s.) 105.77
Sales Per Share 1.19935e+010
EBITDA (p.s.) 9e+009
Qtrly Earnings Growth 16.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow 13,620 (M)

Stock Valuations

PE Ratio 0
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow 11.5

Stock Dividends

Dividend 0
Forward Dividend 1.543e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.